In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Galectin Therapeutics Inc.. Trade Record

NASDAQ:GALT Galectin Therapeutics Inc. stock gains 33.00% Exit Mar 2, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart GALT Feb 9, 2017, priceSeries
About Galectin Therapeutics Inc.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.

Trade Information
Trade Type
LONG
ReliabilityScore™
83.16
Entry Date
Feb 9, 2017
Entry Price
1.25
Sell Date
Mar 2, 2017
Sell Price
1.66
Net Gain
33.00%
Hold Time
14 Trading Days